GSK plc (LON:GSK) Receives Average Rating of "Moderate Buy" from Brokerages

GSK plc (LON:GSK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is GBX 1,862.50 ($24.77).

GSK has been the subject of a number of research reports. Shore Capital reissued a "buy" rating on shares of GSK in a report on Wednesday, April 30th. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research note on Friday, March 28th.

GSK Price Performance

LON GSK opened at GBX 1,394.50 ($18.54) on Monday. The stock has a 50-day simple moving average of GBX 1,410.57 and a 200 day simple moving average of GBX 1,394.97. GSK has a twelve month low of GBX 1,242.50 ($16.52) and a twelve month high of GBX 1,808.50 ($24.05). The stock has a market capitalization of £56.59 billion, a PE ratio of 22.53, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Research analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Activity

In other news, insider Wendy Becker bought 536 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was bought at an average price of GBX 1,515 ($20.15) per share, for a total transaction of £8,120.40 ($10,798.40). Also, insider Emma Walmsley sold 5,473 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.27), for a total value of £79,303.77 ($105,457.14). Corporate insiders own 1.61% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.